EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+2.31%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$434M
AUM Growth
+$434M
(+20%)
Cap. Flow
+$117M
Cap. Flow
% of AUM
26.89%
Top 10 Holdings %
Top 10 Hldgs %
81.24%
Holding
46
New
12
Increased
6
Reduced
2
Closed
10
Top Buys
| 1 |
FibroGen
FGEN
|
$49.9M |
| 2 |
Sangamo Therapeutics
SGMO
|
$22.6M |
| 3 |
Forte Biosciences
FBRX
|
$18.1M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$16M |
| 5 |
Ascendis Pharma
ASND
|
$12.7M |
Top Sells
| 1 |
Aclaris Therapeutics
ACRS
|
$13.2M |
| 2 |
Atara Biotherapeutics
ATRA
|
$8.94M |
| 3 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$5.68M |
| 4 |
Xencor
XNCR
|
$5.62M |
| 5 |
Kura Oncology
KURA
|
$5.38M |
Sector Composition
| 1 | Healthcare | 96.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ironwood Pharmaceuticals
IRWD
$214M
| $70.9M | 12.58% | 3,753,635 +848,120 | +29% | +$16M |
|
2
Assembly Biosciences
ASMB
$190M
| $60.8M | 10.79% | 2,943,164 | – | – |
|
|
3
FibroGen
FGEN
$47.8M
| $51.2M | 9.09% | 1,585,457 +1,543,448 | +3,674% | +$49.9M |
|
4
Galapagos
GLPG
$2.07B
| $44.3M | 7.86% | 578,505 +27,464 | +5% | +$2.1M |
|
|
5
Ascendis Pharma
ASND
$11.8B
| $41.2M | 7.31% | 1,482,600 +456,900 | +45% | +$12.7M |
|
|
6
Sangamo Therapeutics
SGMO
$157M
| $22.6M | 4.01% | +2,568,119 | New | +$22.6M |
|
|
7
Kura Oncology
KURA
$686M
| $18.9M | 3.36% | 2,033,622 -578,284 | -22% | -$5.38M |
|
|
8
Forte Biosciences
FBRX
$137M
| $18.1M | 3.21% | +1,502,373 | New | +$18.1M |
|
9
CytomX Therapeutics
CTMX
$336M
| $12.3M | 2.19% | 794,969 | – | – |
|
10
Editas Medicine
EDIT
$231M
| $12M | 2.14% | +717,107 | New | +$12M |
|
|
CASC
11
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $11.1M | 1.98% | 3,000,000 | – | – |
|
12
Corvus Pharmaceuticals
CRVS
$428M
| $9.74M | 1.73% | +805,000 | New | +$9.74M |
|
13
Fate Therapeutics
FATE
$120M
| $8.22M | 1.46% | 2,537,026 | – | – |
|
|
ATYR
14
aTyr Pharma
ATYR
$527M
| $7.8M | 1.38% | 2,292,659 | – | – |
|
15
Tempest Therapeutics
TPST
$44M
| $5.48M | 0.97% | 3,512,332 | – | – |
|
|
16
Aclaris Therapeutics
ACRS
$209M
| $5.03M | 0.89% | 185,472 -487,628 | -72% | -$13.2M |
|
|
KIN
17
DELISTED
Kindred Biosciences, Inc.
KIN
| $4.69M | 0.83% | 544,880 | – | – |
|
|
TTPH
18
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $4.52M | 0.8% | +633,400 | New | +$4.52M |
|
|
RGLS
19
DELISTED
Regulus Therapeutics
RGLS
| $3.66M | 0.65% | 3,709,144 +2,199,144 | +146% | +$2.17M |
|
|
ACHN
20
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $3.41M | 0.61% | +742,835 | New | +$3.41M |
|
|
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $2.78M | 0.49% | 264,773 | – | – |
|
|
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $2.44M | 0.43% | 767,992 +385,992 | +101% | +$1.22M |
|
23
Adverum Biotechnologies
ADVM
$64.6M
| $2.19M | 0.39% | 874,447 | – | – |
|
24
Minerva Neurosciences
NERV
$16.5M
| $1.98M | 0.35% | +223,802 | New | +$1.98M |
|
|
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.75M | 0.31% | +70,000 | New | +$1.75M |
|